Brief: Biosynex H1 Revenue Down 37% At 142.2 Million Euros

Biosynex SA

18/07/2022 17:15

July 18 (Reuters) - Biosynex SA  ALBIO.PA :
    * IN THE 1ST HALF OF 2022, BIOSYNEX ACHIEVED A TURNOVER OF
€142.2
MILLION, DOWN 37% COMPARED TO THE 1ST HALF OF THE PREVIOUS
FINANCIAL YEAR
    * ENTERS THE POST-COVID-19 ERA WITH A BROADER PRODUCT
PORTFOLIO
AND STRONGER POSITIONS IN PHARMACIES AND PRIVATE AND PUBLIC
LABORATORIES
    * FOR THE SECOND PART OF 2022 AND THE YEAR 2023, THE GROUP
EXPECTS
TO MAINTAIN A LEVEL OF ACTIVITY AROUND COVID-19 PRODUCTS WHICH
WILL DEPEND ON THE EMERGENCE AND VIRULENCE OF FUTURE VARIANTS OF
THE VIRUS
    * IF EPIDEMIC RESURGENCE IN JUNE LEADS BIOSYNEX TO
ANTICIPATE
RECOVERY OF ITS COVID-19 ACTIVITY FROM JULY, CO DOES NOT FORESEE
RETURN TO SALES LEVELS SIMILAR TO THOSE EXPERIENCED IN 2020 AND
2021

Source text for Eikon:  ID:nEQ6VJy5Va 
Further company coverage:  ALBIO.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))